Doctor giving advice for little girl while talking to her father during visit
Image by freepik
Genomic screening is quickly becoming a standard part of healthcare, transitioning from the margins of medicine into everyday practice. This pivotal moment will determine whether it helps prevent disease or leads to unintended consequences. In my book, Destiny’s Child No Longer: Rewriting Genetic Fate, I delve into how the ability to read and alter genes is transforming lives and medical practice.
Picture a future where a simple blood test can outline a person’s health risks for their entire life, influencing their care and family decisions. The path this technology takes, balancing its promises with emerging risks, inequalities, and ethical dilemmas, is still unfolding.
The move towards widespread testing goes beyond a mere upgrade; it signifies a fundamental shift in how privacy, trust, and fairness are handled in healthcare. As costs decrease and interest in broad screening grows, concerns linger about whether systems and safeguards can keep pace. The full societal impact is yet to be fully grasped.
How Will Societies Adapt to the Genomic Revolution
National pilot programs demonstrate the technical feasibility of large-scale genomic testing while also highlighting emerging challenges. The rapid expansion of supporting infrastructure—databases, privacy protections, and consent protocols—raises questions about whether governance and oversight will adapt effectively. Concerns regarding control, access, and the uses of genetic data are increasingly the subject of discussion and scrutiny. The range of possible outcomes remains wide.
As these systems expand rapidly, there is a potential for processes like informed consent to become more routine, potentially reducing individuals’ depth of engagement and understanding. Decisions about genetic data, whether personal or familial, may be made without a full grasp of long-term implications. The reversibility of these decisions is often uncertain, and errors or breaches could have far-reaching consequences. The frequency and extent of such scenarios are still unclear.
When More Data Means More Doubt
The proliferation of DNA testing is often accompanied by the belief that more information will lead to better health outcomes. However, the availability of expanded data has introduced new layers of uncertainty, ambiguous choices, and potential consequences. For example, mammography’s increased sensitivity can reveal findings of uncertain significance, leading to more tests and heightened stress.
Currently, the overdiagnosis rate for breast cancer screening mammography is approximately 12.6% among women aged 40 and older, leading to unnecessary treatments and higher healthcare costs without a significant impact on saving lives. False-positive results and overdiagnosis cost the U.S. healthcare system $4 billion annually.
Similarly, genomic screening may identify conditions that are benign or untreatable, adding financial and psychological strain for individuals and families. Balancing benefit and burden in these cases becomes particularly nuanced, highlighting the complexity of interpreting test results in medicine.
Genomics, Inequality, and Trust
Genomic screening intersects with longstanding issues of health inequality, as many reference databases primarily represent European and Asian populations, raising concerns about result accuracy for other backgrounds. Combined with historical medical exploitation or exclusion experiences, this dynamic could impact trust and participation in genomic initiatives. Whether new technologies will bridge or widen existing disparities remains uncertain and subject to ongoing research.
Genetic data also poses risks of misuse, with potential consequences in areas such as health insurance premiums, job opportunities, or visas based on genetic risk. Real cases exist where adverse decisions were made based on someone’s Huntington’s disease status or other genetic risks.
Regulations like the Genetic Information Nondiscrimination Act offer some protections but are not comprehensive, excluding key areas like life, disability, and long-term care insurance. Storing complete genetic data raises privacy concerns and questions about consent and control over access to a person’s genetic profile in the future.
Who Decides? Ethics and Autonomy
Universal newborn screening brings ethical considerations, as whole-genome sequencing may reveal risks for untreatable diseases. Opting out complexities and parental decisions on uncertain risks add layers to the policy and ethical landscape.
Expanding genomic screening to various settings prompts calls for further research and public dialogue on how societies balance innovation, oversight, and human values integration. The interpretation and integration of genetic knowledge into individual and collective life will shape the future of genomic medicine.
